Overview

A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)

Status:
Recruiting

Trial end date:
2023-05-25

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to assess the efficacy of dupilumab on skin lesions in patients with atopic hand and foot dermatitis. The secondary objectives of the study are: - To assess the efficacy of dupilumab on various other domains (pruritus, pain, sleep loss, health related QoL, work life impairment) in patients with atopic hand and foot dermatitis - To evaluate the safety and tolerability of dupilumab administered to patients with atopic hand and foot dermatitis - To evaluate systemic exposure and immunogenicity of dupilumab in patients with atopic hand and foot dermatitis

Phase:

Phase 3

Details

Lead Sponsor:

Regeneron Pharmaceuticals

Collaborator:

Sanofi